United States:
Ocular Therapeutix Announces Public Offering Of Common Stock
08 February 2017
WilmerHale
To print this article, all you need is to be registered or login on Mondaq.com.
On January 24, 2017, Ocular Therapeutix, Inc. announced the
pricing of its registered underwritten public offering of 3,571,429
shares of its common stock at a public offering price of $7.00 per
share pursuant to a shelf registration statement that was
previously filed with and declared effective by the Securities and
Exchange Commission (SEC). All of the shares in the offering were
sold by the Company.
WilmerHale represented Ocular in this transaction, with Brian Johnson leading the team that included Ryan Mitteness and Avery Reaves.
Visit ocutx.com for the full release.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Finance and Banking from United States
Secured Creditor Chapter 11 Considerations
Trenam Law
Lenders are naturally in a reactionary position when their borrowers file for Chapter 11. Following these tips will help position them for the best possible outcome.
Dos And Don'ts Of Interacting With Bank Regulators
Goodwin Procter LLP
Supervision is a daily fact of life for bank boards and management. Below, we offer strategies for how both board members and members of management can ensure that the supervisory process goes as smoothly as possible.